Home Innotrac Aio!: a point-of-care or a routine analyzer? Analytical performance and plasma/whole blood comparison
Article
Licensed
Unlicensed Requires Authentication

Innotrac Aio!: a point-of-care or a routine analyzer? Analytical performance and plasma/whole blood comparison

  • Sara Altinier , Martina Zaninotto , Monica Maria Mion and Mario Plebani
Published/Copyright: September 21, 2011
Become an author with De Gruyter Brill
Submit Manuscript Author Information
Clinical Chemistry and Laboratory Medicine (CCLM)
From the journal Clinical Chemistry and Laboratory Medicine (CCLM) Volume 44 Issue 10

Abstract

Background and methods: The aim of the present study was to evaluate the analytical performance of the Innotrac Aio! analyzer in measuring the cardiac markers troponin I (TnI), myoglobin (Myo) and creatine kinase-MB (CK-MB), both in lithium heparin plasma and in whole blood.

Results: TnI analytical sensitivity was 0.012μg/L and the concentration corresponding to CV=10% was 0.036μg/L. In healthy subjects, the 99th percentile TnI values were 0.023 and 0.016μg/L in whole blood and in plasma, respectively. One hundred samples were tested both in whole blood and in plasma: TnI-whole-blood=1.16-plasma+0.011, bias=+0.18 (95% CI from –0.22 to +0.59); Myo-whole-blood=1.04-plasma–1.93, bias=+1.08 (95% CI from –6.17 to +8.32); CK-MB-whole-blood=1.11-plasma–0.09, bias=+0.96 (95% CI from –0.53 to +2.45). The method comparison with the RxL Dimension analyzer for TnI and Myo gave the following results: TnI Aio!=0.30 TnI RxL+0.00; bias=−5.80 (95% CI from –7.81 to –3.78), Myo Aio!=1.33 Myo RxL+0.42, bias=+53.09 (95% CI from +38.44 to +67.74).

Conclusions: The analytical performance of the Innotrac Aio! analyzer was satisfactory for all three cardiac markers evaluated and, in particular, the TnI method provided sensitive and accurate results. The most important finding in this study is the possibility to perform the tests as either routine or point-of-care analysis, thus overcoming the variability of results obtained employing different methods.

Clin Chem Lab Med 2006;44:1278–82.

Keywords: cardiac markers; creatine kinase-MB; myoglobin; point-of-care testing; troponin I
Corresponding author: Sara Altinier, Via Giustiniani 2, 35128 Padova, Italy Phone: +39-049-821-8708,

References

1. Rosalki SB, Roberts R, Katus HA, Giannitsis E, Ladenson JH. Cardiac biomarkers for detection of myocardial infarction: perspectives from past to present. Clin Chem 2004; 50:2205–13.10.1373/clinchem.2004.041749Search in Google Scholar PubMed

2. Steindel SJ, Howanitz PJ. Physician satisfaction and emergency department laboratory test turnaround time. Arch Pathol Lab Med 2001; 125:863–71.10.5858/2001-125-0863-PSAEDLSearch in Google Scholar PubMed

3. The Joint European Society of Cardiology/American College of Cardiology Committee. Myocardial infarction redefined – a consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. Eur Heart J 2000;21:1502–13.10.1053/euhj.2000.2305Search in Google Scholar PubMed

4. Fraser CG. Optimal analytical performance for point of care testing. EJIFCC vol 13 no: http.//www.ifcc.org/ejifcc/vol13no1/13011200106.htm.Search in Google Scholar

5. Panteghini M, Apple FS, Christenson RH, Dati F, Mair J, Wu AH. Use of biochemical markers in acute coronary syndromes. IFCC Scientific Division, Committee on Standardization of Markers of Cardiac Damage. Clin Chem Lab Med 1999; 37:687–93.10.1515/CCLM.1999.107Search in Google Scholar PubMed

6. Altinier S, Mion M, Cappelletti A, Zaninotto M, Plebani M. Rapid measurement of cardiac markers on Stratus CS. Clin Chem 2000; 46:991–3.10.1093/clinchem/46.7.991Search in Google Scholar

7. Wu AH, Smith A, Christenson RH, Murakami MM, Apple FS. Evaluation of a point-of-care assay for cardiac markers for patients suspected of acute myocardial infarction. Chim Clin Acta 2004; 346:211–9.10.1016/j.cccn.2004.03.036Search in Google Scholar PubMed

8. Eriksson S, Ilva T, Becker C, Lund J, Porela P, Pulkki K, et al. Comparison of cardiac troponin I immunoassays variably affected by circulating autoantibodies. Clin Chem 2005; 51:548–55.10.1373/clinchem.2004.040089Search in Google Scholar PubMed

9. Zaninotto M, Mion M, Altinier S, Forni M, Plebani M. Quality specifications for biochemical markers of myocardial injury. Chim Clin Acta 2004; 346:65–72.10.1016/j.cccn.2004.02.035Search in Google Scholar PubMed

10. Koerbin G, Tate JR, Potter JM, Hickman PE. The comparative analytical performance of four troponin I assays at low concentration. Ann Clin Biochem 2005; 42:19–23.10.1258/0004563053026925Search in Google Scholar PubMed

11. Panteghini M, Pagani F, Yeo KJ, Apple FS, Christenson RH, Dati F, et al. Committee on standardization of markers of cardiac damage of the IFCC. Evaluation of imprecision for cardiac troponin I assays at low-range concentrations. Clin Chem 2004; 50:327–32.10.1373/clinchem.2003.026815Search in Google Scholar PubMed

12. Pagani F, Stefini F, Panteghini M. Innotrac Aio! Second-generation cardiac assay: imprecision profile and other key characteristics for clinical use. Clin Chem 2004; 50:1271–2.10.1373/clinchem.2004.033258Search in Google Scholar

13. Hedberg P, Valkama J, Puukka M. Analytical performance of time-resolved fluorometry-based Innotrac Aio! Cardiac marker immunoassays. Scand J Clin Lab Invest 2003; 63:55–64.10.1080/00365510310000493Search in Google Scholar

14. Pettersson K, Katajamaki T, Irjala K, Leppanen V, Majamaa-Voltti K, Laitinen P. Time-resolved fluorometry (TRF)-based immunoassay concept for rapid and quantitative determination of biochemical myocardial infarction markers from whole blood, serum and plasma. Luminescence 2000; 15:399–407.10.1002/1522-7243(200011/12)15:6<399::AID-BIO627>3.0.CO;2-3Search in Google Scholar

15. Weber M, Rau M, Madlener K, Elsaesser A, Bankovic D, Mitrovic V, et al. Diagnostic utility of new immunoassays for the cardiac markers cTnI, myoglobin and CK-MB mass. Clin Biochem 2005; 38:1207–30.10.1016/j.clinbiochem.2005.07.011Search in Google Scholar

16. Bunk DM, Welch MJ. Characterization of a new certified reference material for human cardiac troponin I. Clin Chem 2006; 52:212–9.10.1373/clinchem.2005.051359Search in Google Scholar

17. Zaninotto M, Pagani F, Altinier S, Amboni P, Bonora R, Dolci A, et al. Multicenter evaluation of five assays for myoglobin determination. Clin Chem 2000; 46:1631–7.10.1093/clinchem/46.10.1631Search in Google Scholar

Received: 2006-5-26
Accepted: 2006-7-10
Published Online: 2011-9-21
Published in Print: 2006-10-1

©2006 by Walter de Gruyter Berlin New York

Articles in the same Issue

  1. Multiplexed testing in the autoimmunity laboratory
  2. Uncertainty calculation for calibrators and controls of laboratory diagnostic assays
  3. Westgard multirule for calculated laboratory tests
  4. Frequency of a single nucleotide (A2317G) and 56-bp variable number of tandem repeat polymorphisms within the deoxyribonuclease I gene in five ethnic populations
  5. The influence of genetic polymorphisms of cytochrome P450 3A5 and ABCB1 on starting dose- and weight-standardized tacrolimus trough concentrations after kidney transplantation in relation to renal function
  6. Apolipoprotein B gene 3′VNTR polymorphism: association with plasma lipids and coronary heart disease in Han Chinese
  7. Paraoxonase-1 (PON1) activity, but not PON1Q192R phenotype, is a predictor of coronary artery disease in a middle-aged Serbian population
  8. A modified method of prothrombin time/International Normalised Ratio determination in capillary blood and monitoring oral anticoagulant therapy
  9. Inhibition of the ubiquitin-proteasome system: a new avenue for atherosclerosis
  10. Lipid peroxidation and antioxidative status in β-thalassemia major patients with or without hepatitis C virus infection
  11. Role of serum S100B as a predictive marker of fatal outcome following isolated severe head injury or multitrauma in males
  12. Preanalytical and analytical variation of surface-enhanced laser desorption-ionization time-of-flight mass spectrometry of human serum
  13. Effect of nitrogen mustard, a vesicant agent, on lymphocyte energy metabolism
  14. Partitioning reference values of several Gaussian subpopulations with unequal prevalence – a procedure with computer program support
  15. Biovariability of plasma adiponectin
  16. Multicentre evaluation of a new point-of-care test for the determination of NT-proBNP in whole blood
  17. Innotrac Aio!: a point-of-care or a routine analyzer? Analytical performance and plasma/whole blood comparison
  18. Serologic associations of anti-cytoplasmic antibodies identified during anti-nuclear antibody testing
  19. The importance of metrological traceability on the validity of creatinine measurement as an index of renal function: International Federation of Clinical Chemistry and Laboratory Medicine (IFCC)
  20. Effect of seropositive rheumatoid factor on cardiac troponin I measurement using the Access® Immunoassay Analyzer
https://doi.org/10.1515/CCLM.2006.223
Keywords for this article
cardiac markers; creatine kinase-MB; myoglobin; point-of-care testing; troponin I

Articles in the same Issue

  1. Multiplexed testing in the autoimmunity laboratory
  2. Uncertainty calculation for calibrators and controls of laboratory diagnostic assays
  3. Westgard multirule for calculated laboratory tests
  4. Frequency of a single nucleotide (A2317G) and 56-bp variable number of tandem repeat polymorphisms within the deoxyribonuclease I gene in five ethnic populations
  5. The influence of genetic polymorphisms of cytochrome P450 3A5 and ABCB1 on starting dose- and weight-standardized tacrolimus trough concentrations after kidney transplantation in relation to renal function
  6. Apolipoprotein B gene 3′VNTR polymorphism: association with plasma lipids and coronary heart disease in Han Chinese
  7. Paraoxonase-1 (PON1) activity, but not PON1Q192R phenotype, is a predictor of coronary artery disease in a middle-aged Serbian population
  8. A modified method of prothrombin time/International Normalised Ratio determination in capillary blood and monitoring oral anticoagulant therapy
  9. Inhibition of the ubiquitin-proteasome system: a new avenue for atherosclerosis
  10. Lipid peroxidation and antioxidative status in β-thalassemia major patients with or without hepatitis C virus infection
  11. Role of serum S100B as a predictive marker of fatal outcome following isolated severe head injury or multitrauma in males
  12. Preanalytical and analytical variation of surface-enhanced laser desorption-ionization time-of-flight mass spectrometry of human serum
  13. Effect of nitrogen mustard, a vesicant agent, on lymphocyte energy metabolism
  14. Partitioning reference values of several Gaussian subpopulations with unequal prevalence – a procedure with computer program support
  15. Biovariability of plasma adiponectin
  16. Multicentre evaluation of a new point-of-care test for the determination of NT-proBNP in whole blood
  17. Innotrac Aio!: a point-of-care or a routine analyzer? Analytical performance and plasma/whole blood comparison
  18. Serologic associations of anti-cytoplasmic antibodies identified during anti-nuclear antibody testing
  19. The importance of metrological traceability on the validity of creatinine measurement as an index of renal function: International Federation of Clinical Chemistry and Laboratory Medicine (IFCC)
  20. Effect of seropositive rheumatoid factor on cardiac troponin I measurement using the Access® Immunoassay Analyzer
Sign up now to receive a 20% welcome discount
Institutional Access
How does access work?
Have an idea on how to improve our website?
Please write us.
© 2025 De Gruyter Brill
Downloaded on 25.9.2025 from https://www.degruyterbrill.com/document/doi/10.1515/CCLM.2006.223/html
Scroll to top button